The Knockout Punch for HER2 Positive Breast Cancer: Addition of an ADAM10 Inhibitor to the Combination Therapy of Trastuzamab and Lapatinib

The most popular drugs for treating HER2 positive breast cancer are Trastuzumab or lapatinib. Clinical trials in recent years have begun where the two drugs are now being used in combination. Some of the trial results appear to be promising and the combination therapy could provide a new way in which to combat resistance to therapies and improve disease free survival compared to when either drug is used alone. This article describes the benefit of targeting HER2 positive breast cancer with multiple therapies and proposes a novel way in which to treat the disease; to add an ADAM10 inhibitor to the Trastuzumab and lapatinib combination.

अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।

आणविक एंजाइमोलॉजी और औषधि लक्ष्य

में अनुक्रमित

इस पृष्ठ को साझा करें

अमूर्त

The Knockout Punch for HER2 Positive Breast Cancer: Addition of an ADAM10 Inhibitor to the Combination Therapy of Trastuzamab and Lapatinib